Last edition
News about "OrbiMed"
Cellipont Bioservices announces strategic debt facility investment from OrbiMed
The 76,000 sq foot facility will feature significant capabilities including process and analytical development and manufacturing services for CAR-T, IPSC, MSC and other types of cell therapies
OrbiMed | 22/03/2023 | By Sudeep Soparkar | 452
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members